159 related articles for article (PubMed ID: 16416745)
41. The analysis of factor VIII.
Giddings JC
Med Lab Sci; 1982 Oct; 39(4):339-43. PubMed ID: 6817015
[No Abstract] [Full Text] [Related]
42. von Willebrand factor abnormalities in two patients with uraemia.
Rodeghiero F; Castaman G; Lombardi R; Mannucci PM
Lancet; 1988 Oct; 2(8618):1016-7. PubMed ID: 2902444
[No Abstract] [Full Text] [Related]
43. Epidural analgesia for parturients with type 1 von Willebrand disease.
Marrache D; Mercier FJ; Boyer-Neumann C; Roger-Christoph S; Benhamou D
Int J Obstet Anesth; 2007 Jul; 16(3):231-5. PubMed ID: 17509867
[TBL] [Abstract][Full Text] [Related]
44. Toward a new paradigm for the identification and functional characterization of von Willebrand disease.
Favaloro EJ
Semin Thromb Hemost; 2009 Feb; 35(1):60-75. PubMed ID: 19308894
[TBL] [Abstract][Full Text] [Related]
45. Persistent factor VIII-dependent factor X activation on endothelial cells is independent of von Willebrand factor.
Brinkman HJ; van Mourik JA; Mertens K
Blood Coagul Fibrinolysis; 2008 Apr; 19(3):190-6. PubMed ID: 18388497
[TBL] [Abstract][Full Text] [Related]
46. Procoagulant factors and the risk of myocardial infarction in young women.
Tanis B; Algra A; van der Graaf Y; Helmerhorst F; Rosendaal F
Eur J Haematol; 2006 Jul; 77(1):67-73. PubMed ID: 16608503
[TBL] [Abstract][Full Text] [Related]
47. Combined clotting factor deficiencies: experience at a single hemophilia treatment center.
O'Brien SH; Ritchey AK; Ragni MV
Haemophilia; 2007 Jan; 13(1):26-9. PubMed ID: 17212721
[TBL] [Abstract][Full Text] [Related]
48. Corticosteroid and factor VIII.
Ozsoylu S
Acta Haematol; 1989; 81(4):222. PubMed ID: 2502899
[No Abstract] [Full Text] [Related]
49. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.
Favaloro EJ; Kershaw G; McLachlan AJ; Lloyd J
Semin Thromb Hemost; 2007 Nov; 33(8):745-58. PubMed ID: 18175280
[TBL] [Abstract][Full Text] [Related]
50. Determination of von Willebrand factor activity: evaluation of the HaemosIL assay in comparison with established procedures.
Sucker C; Senft B; Scharf RE; Zotz RB
Clin Appl Thromb Hemost; 2006 Jul; 12(3):305-10. PubMed ID: 16959683
[TBL] [Abstract][Full Text] [Related]
51. von Willebrand factor standards for plasma and concentrate testing.
Hubbard AR
Semin Thromb Hemost; 2006 Jul; 32(5):522-8. PubMed ID: 16862526
[TBL] [Abstract][Full Text] [Related]
52. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel.
James AH; Kouides PA; Abdul-Kadir R; Edlund M; Federici AB; Halimeh S; Kamphuisen PW; Konkle BA; MartÃnez-Perez O; McLintock C; Peyvandi F; Winikoff R
Am J Obstet Gynecol; 2009 Jul; 201(1):12.e1-8. PubMed ID: 19481722
[TBL] [Abstract][Full Text] [Related]
53. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
54. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma.
Caudill JS; Nichols WL; Plumhoff EA; Schulte SL; Winters JL; Gastineau DA; Rodriguez V
Transfusion; 2009 Apr; 49(4):765-70. PubMed ID: 19192257
[TBL] [Abstract][Full Text] [Related]
55. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
56. Factor VIII related antigen: an improved enzyme immunoassay.
Short PE; Williams CE; Picken AM; Hill FG
Med Lab Sci; 1982 Oct; 39(4):351-5. PubMed ID: 6817017
[No Abstract] [Full Text] [Related]
57. The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement.
Lippi G; Franchini M; Targher G; Poli G; Guidi GC
Clin Chim Acta; 2007 Jun; 381(2):167-70. PubMed ID: 17433810
[TBL] [Abstract][Full Text] [Related]
58. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor.
Platokouki H; Pergantou H; Xafaki P; Komitopoulou A; Aronis S
Haemophilia; 2009 Mar; 15(2):617-9. PubMed ID: 19175417
[No Abstract] [Full Text] [Related]
59. FVIIICag assay on fresh and stored plasma samples using two monoclonal antibodies: an anti FVIIIC and an anti FVIIIR:Ag.
Francis SE; Joshua DE; Power PA; Rickard KA; Kronenberg H
Pathology; 1987 Jan; 19(1):104-5. PubMed ID: 3108837
[No Abstract] [Full Text] [Related]
60. Thrombin-generating capacity in patients with von Willebrand's disease.
Rugeri L; Beguin S; Hemker C; Bordet JC; Fleury R; Chatard B; Negrier C; Dargaud Y
Haematologica; 2007 Dec; 92(12):1639-46. PubMed ID: 18055987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
